Opko Health, Inc. (OPK): Long-Term Debt
$343.97M
As of 2025-12-31
$349.05M
As of 2026-06-30
+10.3%
3-year compound annual growth
+6.5%
5-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $343.97M | -21.3% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $437.20M | n/m | 2026-02-26, Balance as of period end |
| 2023-12-31 | $50.6K | -100.0% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $256.25M | +24.8% | 2024-03-01, Balance as of period end |
| 2021-12-31 | $205.27M | -18.3% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $251.21M | -7.1% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $270.30M | n/a | 2021-02-18, Balance as of period end |
| No annual figure between 2012-12-31 and 2019-12-31. | |||
| 2012-12-31 | $5.15M | n/a | 2013-03-18, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Opko Health, Inc. (OPK) | 2025-12-31 | $343.97M | -21.3% |
| Insmed Inc (INSM) | 2025-12-31 | $546.77M | -51.3% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $93.16M | +12.5% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $372.19M | -36.4% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $2.01B | n/a |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $589.70M | -15.8% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $163.66M | -8.7% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $202.83M | +34.5% |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $1.81B | +44.6% |
Compare OPK, INSM, HCM, PCRX side by side · Screen every company in Pharmaceutical Preparations ↗